Ozone therapy in colorectal cancer
Frontiers in Oncology · 30.10.2026 · 16
DOI: 10.3389/fonc.2026.1925327 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 30.10.2026. Verfasst von Yanchu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Oncology Ward, West China Hospital of Sichuan University, Chengdu, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and metastatic progression, recurrence, chemoresistance, and treatment-related toxicity continue to limit outcomes. Medical ozone has attracted interest as a potential adjunct because, after reacting with biological fluids, it generates short-lived redox mediators such as hydrogen peroxide and lipid oxidation products that may influence NRF2/Keap1, NF-κB, HIF-1α, mitochondrial apoptosis, cytokine signaling, and the tumor microenvironment. However, current CRC-specific evidence is limited and heterogeneous. Experimental studies using CRC cell lines and animal models suggest possible effects on apoptosis, oxidative stress, inflammatory modulation, hypoxia-related pathways, and chemosensitivity, but these findings remain preclinical and are not sufficient to establish antitumor efficacy. Clinical evidence in CRC patients is scarce and mainly relates to supportive care, including radiation-induced rectal injury, chronic treatment-related symptoms, and chemotherapy-induced peripheral neuropathy, rather than tumor response or survival. Importantly, ozone biology is context dependent: activation of adaptive antioxidant responses may protect normal tissues but could also enhance tumor cell stress tolerance under certain conditions. Route-specific safety is also critical, as inhaled ozone is toxic, whereas non-inhalational approaches require standardized dosing and monitoring. Overall, ozone therapy should be considered an investigational adjunct in CRC, with future studies requiring rigorous trial design, biomarker stratification, standardized administration protocols, and clear separation of anticancer endpoints from symptom-control outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Head and Neck Oncology Ward, West China Hospital of Sichuan University, Chengdu, China.
- Department of Oncology, Chengdu Fuxing Hospital, Sichuan, China.
- Department of Center for Hepatobiliary Pancreatic Splenic Diseases, Zigong Fourth People's Hospital, Sichuan, China.
- West China School of Nursing, Sichuan University; Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, Chengdu, China.
Zitieren
APA
Li, Y., Pu, R., Yang, S., Chen, H., & Zhang, X. (2026). Ozone therapy in colorectal cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1925327
Vancouver
Li Y, Pu R, Yang S, Chen H, Zhang X. Ozone therapy in colorectal cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1925327
BibTeX
@article{Li2026,
author = {Li, Yanchu and Pu, Rong and Yang, Sen and Chen, Hongxiu and Zhang, Xiaoxia},
title = {Ozone therapy in colorectal cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1925327}
}
EUVIMED